exRNAdisease

General Information

Database ID:

exR0076875

RNA Name:

MKNK2

RNA Type:

mRNA

Chromosome:

chr19

Starnd:

Coordinate:

Start Site(bp):

2037465

End Site(bp):

2051244

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABCD1	chrX	153724856	153744755	+
ABCF2	chr7	151207837	151227166	-
ABHD17A	chr19	1876810	1885547	-
AC010422.3	chr19	12643831	12648397	-
AC010531.1	chr16	87302876	87334273	-
ACADVL	chr17	7217125	7225266	+
ACAT2	chr6	159762045	159779112	+
ACSL4	chrX	109624244	109733403	-
ACTB	chr7	5527148	5563784	-
ACTG1	chr17	81509971	81523847	-
ADGRE5	chr19	14380501	14408725	+
ADPGK	chr15	72751369	72785846	-
AHCY	chr20	34280268	34311802	-
AIP	chr11	67483026	67491103	+
AK2	chr1	33007940	33080996	-
AK4	chr1	65147549	65232145	+
AL133352.1	chr10	100505628	100529881	-
AL590764.2	chrX	71103987	71111575	-
AL928654.3	chr14	105487199	105492267	+
ALDH2	chr12	111766887	111817532	+
ALDOA	chr16	30064164	30070457	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-1321	chrX	85835832	85835849	+
hsa-miR-3654	chr7	133034860	133034878	-

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC008738.7	chr19	33207129	33207639	+
AC010997.3	chr10	75279726	75401246	-
AC016876.2	chr17	7581964	7584086	-
AC245884.11	chr19	54308915	54337168	-
AD000090.1	chr19	35557956	35581954	+
AL049796.1	chr1	93847174	93848939	+
AL138756.1	chr9	112028570	112039143	-

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference